Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-08-04
2000-08-15
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514320, 514408, A67K 31445
Patent
active
061037400
ABSTRACT:
A method of safely lowering platelet count in a human which comprises the administration to a human in need thereof of an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.3 are, independently, --H, --CH.sub.3, --CO(C.sub.1 -C.sub.6 alkyl), or --COAr, where Ar is optionally substituted phenyl;
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones et al.
patent: 4447620 (1984-05-01), Sih et al.
patent: 4847276 (1989-07-01), Yarrington
patent: 5075321 (1991-12-01), Schreiber
patent: 5391557 (1995-02-01), Cullinan et al.
patent: 5441965 (1995-08-01), Sall et al.
patent: 5445941 (1995-08-01), Yang
patent: 5476862 (1995-12-01), Calnek et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5508292 (1996-04-01), Sall et al.
Draper et al., "Effects of Raloxifene (LY139481 HCl) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women", Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., "Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Bryant et al., "Raloxifene is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolick et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Anti-estrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene an Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;".Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.
Black et al., "Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109;1981, 987-989.
Black, L.J. "Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018," In: Homone Antagonists, 129-82, 1982 (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.
Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl)ethoxyl]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962-966.
Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-91-piperidinyl)etho xy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066.
Dina M. Bitar et al., Suppression of Experimental Autoimmune Encephalomyelitis by the Oral Administration of Myelin Basic Protein, Cellular Immunology 112, 364-370, 1988.
Paul J. Higgins, et al., Suppression of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myelin Basic Protein and its Fragments, The Journal of Immunology, vol. 140(2), 440-445, Jan. 15, 1988.
Oral Tolerance to Myelin Basic Protein and Natural Recovery from Experimental Autoimmune Encephalomyelitis Are Associated with Downregulation of Inflammatory Cytokines and Differential Upregultion of Transforming Growth Factor .beta., Intererleukin 4, and Prostaglandin E Expression In the Brain, J. Exp. Med., vol., 176, 1355-1364, Nov. 1992.
C. D. Jones, et al. Antiestrogens. 2. Structure-Activity Studies in a Series of 3-Aroyl-2-arylbenzo{b}thiophene Derivatives Leading to{6-Hyddroxy-2-(4-hydroxyphenyl)benzo{b}thien-3-yl][4-[2-(1-piperidinyl)e thoxy]-phenyl]methanone Hydrochloride (LY156758), A remarkably Effective Estrogen Antagonist With Only Minimal Intrinsic Estrogenicity, J. Med. Chem., 1984, 27, 1057-1066.
A Hendrick, et al., Tamoxifen and Thromboembolism, Journal of the American Medical Association, vol. 243, No. 6, Feb. 8, 1980.
Radwanska, E., The Role of Reproductive Hormones in Vascular Diseases and Hypertension, Steroids, 58(12), 605, Dec. 1993.
Pfilger, et al., Acta Med. Austriaca, 18(3), 68-72, 1991.
Database HCAPLUS on STN, AN 1988:32668, "Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells". Cell, (Cambridge, Mass.) 1987, 48(3), 417-428.
Boudreaux William R.
Eli Lilly and Company
Fay Zohreh
Sales James J.
LandOfFree
Methods for lowering platelet counts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for lowering platelet counts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for lowering platelet counts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2007280